Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab

Journal of Neuro-Oncology

Volumn 106, Issue 1, 2012, Pages 111-119

  Ellingson, Benjamin M ^a   Cloughesy, Timothy F ^a   Lai, Albert ^a   Nghiemphu, Phioanh L ^a   Lalezari, Shadi ^a   Zaw, Taryar ^a   Motevalibashinaeini, Kourosh ^a   Mischel, Paul S ^a   Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Bevacizumab; DQT2; GBM; Glioblastoma; Magnetic resonance imaging; MRI

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DEXAMETHASONE; IRINOTECAN; LOMUSTINE;

ARTICLE; BRAIN EDEMA; CANCER RECURRENCE; CLINICAL ARTICLE; DIFFERENTIAL QUANTITATIVE T2 RELAXOMETRY MAPPING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN EDEMA; BRAIN MAPPING; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83055181491     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0638-x     Document Type: Article

References (41)

1. H Huang J Held-Feindt R Buhl HM Mehdorn R Mentlein 2005 Expression of VEGF and its receptors in different brain tumors Neurol Res 27 4 371 377 15949234 10.1179/016164105X39833 1:CAS:528:DC%2BD2MXlslemsL8%3D
2. KH Plate G Breier W Risau 1994 Molecular mechanisms of developmental and tumor angiogenesis Brain Pathol 4 3 207 218 7524960 10.1111/j.1750-3639.1994. tb00835.x 1:CAS:528:DyaK2cXmt1Omtr4%3D (Pubitemid 24261926)
3. J Holash PC Maisonpierre D Compton P Boland CR Alexander D Zagzag GD Yancopoulos SJ Weigand 1999 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 5422 1994 1998 10373119 10.1126/science.284.5422.1994 1:CAS:528:DyaK1MXktVWntrY%3D (Pubitemid 29309448)
4. DG Duda TT Batchelor CG Willett RK Jain 2007 VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects Trends Mol Med 13 6 223 230 17462954 10.1016/j.molmed.2007.04.001 1:CAS:528:DC%2BD2sXmtVGgtLY%3D (Pubitemid 46836870)
5. PL Nghiemphu W Liu Y Lee T Than C Graham A Lai RM Green WB Pope LM Liau PS Mischel SF Nelson R Elashoff TF Cloughesy 2009 Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience Neurology 72 14 1217 1222 19349600 10.1212/01.wnl.0000345668.03039.90 1:CAS:528:DC%2BD1MXjslKrsrs%3D
6. JJ Vredenburgh A Desjardins JE Herndon JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 17317837 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D (Pubitemid 46424067)
7. AH Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WK Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 4733 4740 19720927 10.1200/JCO.2008.19.8721 1:CAS:528:DC%2BD1MXhtlGgtbbM
8. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Morosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvent temozolomide for glioblastoma N Engl J Med 352 10 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
9. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 7 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
10. FM Iwamoto LE Abrey K Beal PH Gutin ML Rosenblum VE Reuter LM DeAngelis AB Lassman 2009 Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73 15 1200 1206 19822869 10.1212/WNL. 0b013e3181bc0184 1:CAS:528:DC%2BD1MXht1antrfK
11. AD Norden GS Young K Setayesh A Muzikansky R Klufas GL Ross AS Ciampa LG Ebbeling B Levy J Drappatz S Kesari PY Wen 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 10 779 787 18316689 10.1212/01.wnl.0000304121.57857.38 1:CAS:528: DC%2BD1cXitlyqs7o%3D
12. PY Wen DR Macdonald DA Reardon TF Cloughesy AG Sorensen E Galanis JF de Groot W Wick MR Gilbert AB Lassman CI Tsien T Mikkelsen ET Wong MC Chamberlain R Stupp KR Lamborn MA Vogelbaum MJ van den Bent SM Chang 2010 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 1963 1972 20231676 10.1200/JCO.2009.26.3541
13. RM Zuniga R Torcuator R Jain J Anderson T Doyle S Ellika L Schultz T Mikkelsen 2009 Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 3 329 335 18953493 10.1007/s11060-008-9718-y 1:CAS:528:DC%2BD1MXjvFemtQ%3D%3D
14. WB Pope J Sayre A Perlina JP Villablanca PS Mischel TF Cloughesy 2005 MR imaging correlates of survival in patients with high-grade gliomas AJNR Am J Neuroradiol 26 10 2466 2474 16286386
15. RW Cox A Jesmanowicz 1999 Real-time 3D image registration for functional MRI Magn Reson Med 42 1014 1018 10571921 10.1002/(SICI)1522-2594(199912)42: 6<1014::AID-MRM4>3.0.CO;2-F 1:STN:280:DC%2BD3c%2FktVCktA%3D%3D
16. F Earnest IV PJ Kelly BW Scheithauer BA Kall TL Cascino RL Ehman GS Forbes PL Axley 1988 Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy Radiology 166 3 823 827 2829270 (Pubitemid 18058950)
17. PJ Kelly C Daumas-Duport DB Kispert BA Kall BW Scheithauer JJ Illig 1987 Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms J Neurosurg 66 6 865 874 3033172 10.3171/jns.1987.66.6.0865 1:STN:280:DyaL2s7pslGqtw%3D%3D (Pubitemid 17085708)
18. PJ Kelly C Daumas-Duport BW Scheithauer BA Kall DB Kispert 1987 Stereotactic histological correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms Mayo Clin Proc 62 6 450 459 3553757 1:STN:280:DyaL2s3gtValtA%3D%3D (Pubitemid 17084816)
19. M Watanabe R Tanaka N Takeda 1992 Magnetic resonance imaging and histopathology of cerebral gliomas Neuroradiology 34 6 463 469 1436452 10.1007/BF00598951 1:STN:280:DyaK3s%2FmtlOqtw%3D%3D
20. M Brant-Zawadski D Norman TH Newton 1984 Magnetic resonance imaging of the brain: the optimal screening technique Radiology 152 71 77 (Pubitemid 14083156)
21. TN Byrne 1994 Imaging of gliomas Semin Oncol 21 162 171 8153662 1:STN:280:DyaK2c3gsVKrsg%3D%3D (Pubitemid 24125956)
22. HW Husstedt M Sickert H Köstler B Haubitz H Becker 2000 Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors Eur Radiol 10 5 745 752 10823626 10.1007/s003300050997 1:STN:280:DC%2BD3czosFamtQ%3D%3D (Pubitemid 30321084)
23. K Tsuchiya Y Mizutani J Hachiya 1996 Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumors AJNR Am J Neuroradiol 17 6 1081 1086 8791919 1:STN:280:DyaK28zosVSjtg%3D%3D (Pubitemid 26198514)
24. M Essig H Hawighorst SO Schoenberg R Engenhart-Cabillic M Fuss J Debus I Zuna MV Knopp G van Kaick 1998 Fast fluid-attenuated inversion-recovery (FLAIR) MRI in the assessment of intraaxial brain tumors J Magn Reson Imaging 8 4 789 798 9702879 10.1002/jmri.1880080407 1:STN:280:DyaK1czms1Cguw%3D%3D (Pubitemid 28357585)
25. BM Ellingson TF Cloughesy A Lai PL Nghiemphu PS Mischel WB Pope 2011 Quantitative volumetric analysis of conventional magnetic resonance imaging response in recurrent glioblastoma treated with bevacizumab Neuro Oncol 13 401 409 21324937 10.1093/neuonc/noq206 1:CAS:528:DC%2BC3MXnvFKkt78%3D
26. KP Whittall AL Mackay DA Graeb RA Nugent DKB Li DW Paty 1997 In vivo measurement of T2 distributions and water contents in normal human brain Magn Reson Med 37 1 34 43 8978630 10.1002/mrm.1910370107 1:STN:280: DyaK2s7jtlagsQ%3D%3D (Pubitemid 27008828)
27. S Ananthnarayan J Bahng J Roring P Nghiemphu A Lai T Cloughesy WB Pope 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol 88 3 339 347 18389177 10.1007/s11060-008-9573-x
28. F Bokstein S Shpigel DT Blumenthal 2008 Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 10 2267 2273 18327820 10.1002/cncr.23401 1:CAS:528:DC%2BD1cXmt1CnsL8%3D (Pubitemid 351628638)
29. I Fischer CH Cunliffe RJ Bollo S Raza D Monoky L Chiriboga EC Parker JG Golfinos PJ Kelly EA Knopp ML Gruber D Zagzag A Narayana 2008 High-grade glioma before and after treatment with radiation and Avastin: initial observations Neuro Oncol 10 5 700 708 18697955 10.1215/15228517-2008-042
30. WB Pope A Lai P Nghiemphu P Mischel TF Cloughesy 2006 MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 8 1258 1260 16636248 10.1212/01.wnl.0000208958.29600.87 1:CAS:528: DC%2BD28XjtFOrtLs%3D (Pubitemid 43739717)
31. BA Moffat TL Chenevert TS Lawrence CR Meyer TD Johnson Q Dong CI Tsien S Mukherji DJ Quint SS Gebarski PL Robertson L Junck A Rehemtulla BD Ross 2005 Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response Proc Natl Acad Sci 102 15 5524 5529 15805192 10.1073/pnas.0501532102 1:CAS:528:DC%2BD2MXjslaqtrk%3D (Pubitemid 40530291)
32. DA Hamstra CJ Galbán CR Meyer TD Johnson PC Sundgren CI Tsien TS Lawrence L Junck DJ Ross A Rehemtulla BD Ross TL Chenevert 2008 Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival J Clin Oncol 26 10 3387 3394 18541899 10.1200/JCO.2007.15.2363
33. BM Ellingson MG Malkin SD Rand JM Connelly C Quinsey PS LaViolette DP Bedekar KM Schmainda 2010 Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity J Magn Reson Imaging 31 3 538 548 20187195 10.1002/jmri.22068
34. CJ Galbán TL Chenevert CR Meyer C Tsien TS Lawrence DA Hamstra L Junck PC Sundgren TD Johnson DJ Ross A Rehemtulla BD Ross 2009 The parametric response map is an imaging biomarker for early cancer treatment outcome Nat Med 15 5 572 576 19377487 10.1038/nm.1919
35. C Di Perri M Battaglini ML Stromillo ML Bartolozzi L Guidi A Federico N SDe Stefano 2008 Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis Arch Neurol 65 2 236 243 18268194 10.1001/archneurol.2007.51 (Pubitemid 351240787)
36. W Chen S Delaloye DH Silverman C Geist J Czernin J Sayre N Satyamurthy W Pope A Lai ME Phelps T Cloughesy 2007 Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 30 4714 4721 17947718 10.1200/JCO.2006.10.5825 1:CAS:528:DC%2BD2sXhtlCgsLjL (Pubitemid 350086472)
37. AG Sorensen TT Batchelor WT Zhang PJ Chen P Yeo M Wang D Jennings PY Wen J Lahdenranta M Ancukiewicz E di Tomaso DG Duda RK Jain 2009 A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 13 5296 5300 19549889 10.1158/0008-5472.CAN-09-0814 1:CAS:528: DC%2BD1MXnvFWqurY%3D
38. WB Pope HJ Kim J Huo J Alger MS Brown D Gjertson V Sai JR Young L Tekchandani TF Cloughesy PS Mischel A Lai PL Nghiemphu S Rahmanuddin J Goldin 2009 Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment Radiology 252 1 182 189 19561256 10.1148/radiol. 2521081534
39. BM Ellingson MG Malkin SD Rand A Hoyt J Connelly DP Bedekar SN Kurpad KM Schmainda 2009 Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions Proc Int Soc Mag Reson Med 17 1010
40. BM Ellingson MG Malkin SD Rand PS LaViolette JM Connelly WM Mueller KM Schmainda 2011 Volumetric analysis of functional diffusion maps (fDMs) is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas J Neurooncol 102 95 103 20798977 10.1007/s11060-010-0293-7
41. CS Georgiades R Itoh X Golay PC van Zijl ER Melhem 2001 MR imaging of the human brain at 1.5 T: regional variations in transverse relaxation rates in the cerebral cortex AJNR Am J Neuroradiol 22 9 1732 1737 11673169 1:STN:280:DC%2BD3Mnjs1Khtg%3D%3D (Pubitemid 32999584)